![](/img/cover-not-exists.png)
Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development
David G OrloffVolume:
87
Year:
2001
Language:
english
Pages:
7
DOI:
10.1016/s0002-9149(01)01423-0
File:
PDF, 75 KB
english, 2001